The present authors performed an open-label pilot analyze that administered psilocybin to fifteen therapy-resistant tobacco/nicotine-dependent smokers, from the context of cognitive behavioral therapy for using tobacco cessation [fifty eight]. Contributors had been administered ~0.29 mg/kg oral psilocybin within the participant’s goal date to Sto